John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital, Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Yau, James M., John H. Alexander, Gail Hafley, Kenneth W. Mahaffey, Michael J. Mack, Nicholas Kouchoukos, Abhinav Goyal, et al. “Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)..” Am J Cardiol 102, no. 5 (September 1, 2008): 546–51. https://doi.org/10.1016/j.amjcard.2008.04.069.

PMID
18721510
Full Text

Chan, Mark Y., Mauricio G. Cohen, Christopher K. Dyke, Shelley K. Myles, Laura G. Aberle, Min Lin, James Walder, et al. “Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease..” Circulation 117, no. 22 (June 3, 2008): 2865–74. https://doi.org/10.1161/CIRCULATIONAHA.107.745687.

PMID
18506005
Full Text

Chan, M. Y., C. P. Rusconi, J. H. Alexander, R. M. Tonkens, R. A. Harrington, and R. C. Becker. “A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor..” J Thromb Haemost 6, no. 5 (May 2008): 789–96. https://doi.org/10.1111/j.1538-7836.2008.02932.x.

PMID
18284597
Full Text

MEND-CABG II Investigators, Jean-Claude, John H. Alexander, Robert W. Emery, Michel Carrier, Stephen J. Ellis, Rajendra H. Mehta, Vic Hasselblad, et al. “Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial..” Jama 299, no. 15 (April 16, 2008): 1777–87. https://doi.org/10.1001/jama.299.15.joc80027.

PMID
18381567
Full Text

Mehta, Rajendra H., John H. Alexander, Robert Emery, Stephen J. Ellis, Vic Hasselblad, Ahmad Khalil, Michel Carrier, Robert A. Harrington, Jean-Claude Tardif, and Jean-Claude MEND-CABG II Investigators. “A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale..” Am Heart J 155, no. 4 (April 2008): 600–608. https://doi.org/10.1016/j.ahj.2008.01.002.

PMID
18371465
Full Text

Magee, Mitchell J., John H. Alexander, Gail Hafley, T Bruce Ferguson, C Michael Gibson, Robert A. Harrington, Eric D. Peterson, et al. “Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV..” Ann Thorac Surg 85, no. 2 (February 2008): 494–99. https://doi.org/10.1016/j.athoracsur.2007.10.008.

PMID
18222251
Full Text

Olenchock, Stephen A., Dimitri Karmpaliotis, William J. Gibson, Sabina A. Murphy, Matthew C. Southard, Lauren Ciaglo, Jacqueline Buros, et al. “Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters..” Ann Thorac Surg 85, no. 2 (February 2008): 520–24. https://doi.org/10.1016/j.athoracsur.2007.10.061.

PMID
18222256
Full Text

Harrington, R. A., J. H. Alexander, J. S. Hochman, H. R. Reynolds, V. Dzavik, and F. J. Van De Werf. “Tilarginine in patients with acute myocardial infarction and cardiogenic shock - In reply [7].” Journal of the American Medical Association 298, no. 9 (September 5, 2007): 972–73. https://doi.org/10.1001/jama.298.9.972.

Full Text

Cohen, Marc, Deepak L. Bhatt, John H. Alexander, Gilles Montalescot, Christoph Bode, Timothy Henry, Jean-Francois Tamby, et al. “Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial..” Circulation 115, no. 20 (May 22, 2007): 2642–51. https://doi.org/10.1161/CIRCULATIONAHA.106.653428.

PMID
17502577
Full Text

Pages